<DOC>
	<DOCNO>NCT00656318</DOCNO>
	<brief_summary>Thus , propose study follow Specific Aims Hypotheses : 1 . To determine menstruate woman age 18-45 whether OCP contain ethinyl estradiol ( EE ) progestin ethinydiol diacetate ( ED ) increase cortical GABA concentration measure use proton magnetic resonance spectroscopy ( 1H-MRS ) OCP contain EE progestin norethindrone ( NOR ) . 2 . To determine relationship change occipital GABA concentration acute OCP administration negative affect chronic OCP administration two menstrual cycle .</brief_summary>
	<brief_title>Impact Oral Contraceptives GABA Neurosteroids</brief_title>
	<detailed_description>Approximately 11.6 million woman United States use oral contraceptive ( OCs ) year . The vast majority OCs combine estrogen type progestin , progesterone-like substance one pill take daily . Depression negative change mood , apparently result use OCs , think one main reason woman miss pill stop take oral contraceptive pill ( OCPs ) altogether . Clinical observation woman develop depression take progestin OCs add progestin menopausal estrogen therapy lead speculation progestin likely culprit negative mood change woman use combined OCPs . The current study design investigate role progestin development mood symptom OCP user . Women participate study receive one two different OCPs three month . Their mood take OCPs compare mood prior use OCPs . In addition , woman undergo brain imaging study first dose OCP determine whether acute change brain chemistry response OCP predict change mood OCP use . By choose OCPs estrogen product 2 different type progestin hope determine whether one type progestin likely result negative mood . Determining factor contribute emergence depression OC use first step develop new oral contraceptive health outcome ultimately improve compliance OCP use . Reducing side effect OCPs likely improve compliance thus decrease prevalence unwanted pregnancy .</detailed_description>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Aged 18 42 year old able give voluntary write informed consent . Willing complete daily log mood symptom 3 consecutive menstrual cycle . Be OCPs least 3 menstrual period prior begin study willing go OCPs study . Provide documentation normal PAP smear , pelvic breast examination within previous 12 month prior enrollment . Have regular menstrual cycle 28 32 day length prior enrollment . The screening cycle must ovulatory confirmed plasma progesterone level &gt; 3 ng/ml luteal phase . Negative pregnancy blood test admission ; negative urine pregnancy test MRS test day . Presence DSMIV Axis I disorder , except possible mild moderate PMS/PMDD , within previous 12 month . Lifetime history psychotic disorder , include bipolar disorder . Meeting DSMIV criterion psychoactive substance ( include nicotine ) abuse/dependence within precede 6 month . A history serious medical neurological illness , include ( limit ) major cardiovascular disease , hypertension ( SBP &gt; 140 mm Hg DBP &gt; 90 mm Hg ) , intracranial mass lesion , seizure disorder , severe hepatic renal disease , unstable endocrine metabolic disease , unstable hematologic disease , gynecologic cancer gallbladder disease , venous thromboembolism , stroke . Diabetes present one cardiovascular risk factor hypercholesterolemia hypertension . Hypercholesterolemia LDL &gt; 160 mg/dl . Use psychotropic medication within previous month . Alcohol consumption great 7 drinks/week . Current pregnancy planning become pregnant course study . Metallic implant . History suspect claustrophobia . Migraine headaches &gt; 35 yo . Weigh &gt; 300 lb ( 4T magnet weight limit &lt; 300 lb )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>woman</keyword>
	<keyword>menses</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>Healthy menstruating female</keyword>
</DOC>